Patents by Inventor David S. Alberts
David S. Alberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9320764Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.Type: GrantFiled: February 1, 2011Date of Patent: April 26, 2016Assignee: TOPICAL TECHNOLOGIES, INC.Inventor: David S. Alberts
-
Publication number: 20110166108Abstract: The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer.Type: ApplicationFiled: December 8, 2010Publication date: July 7, 2011Inventors: Martin STOGNIEW, David S. ALBERTS, Edward H. KAPLAN
-
Publication number: 20110123469Abstract: A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.Type: ApplicationFiled: February 1, 2011Publication date: May 26, 2011Applicant: TOPICAL TECHNOLOGIES, INC.Inventor: David S. Alberts
-
Publication number: 20100226946Abstract: A kit for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state.Type: ApplicationFiled: March 4, 2009Publication date: September 9, 2010Applicant: TOPICAL TECHNOLOGIES, INC.Inventor: David S. Alberts
-
Publication number: 20080153891Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.Type: ApplicationFiled: December 6, 2007Publication date: June 26, 2008Applicant: The Arizona Board of RegentsInventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
-
Publication number: 20080146653Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.Type: ApplicationFiled: December 6, 2007Publication date: June 19, 2008Applicant: The Arizona Board of RegentsInventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
-
Patent number: 7105575Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: May 3, 2002Date of Patent: September 12, 2006Assignee: Medimmune Oncology Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Publication number: 20040106588Abstract: A method for treating pre-cancerous conditions including non-cancerous lesions and non-invasive carcinoma insitu, in cutaneous, and muco-cutaneous regions of the body includes topical application of combinations containing alpha-DFMO and an anti-inflammatory agent selected from the group comprising a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, or a combination thereof. The conditions which may be topically treated with the combination of the present invention include actinic keratoses, vulvar neoplasia, and pre-cancerous conditions of the lip, nostrils, nails, and anus. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO.Type: ApplicationFiled: September 3, 2003Publication date: June 3, 2004Inventors: David S. Alberts, Robert T. Dorr
-
Publication number: 20040043975Abstract: Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.Type: ApplicationFiled: September 3, 2003Publication date: March 4, 2004Applicant: TOPICAL TECHNOLOGIES, INC.Inventors: David S. Alberts, Robert T. Dorr
-
Publication number: 20030129208Abstract: Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha-DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each such component by itself.Type: ApplicationFiled: January 7, 2002Publication date: July 10, 2003Inventors: David S. Alberts, Robert T. Dorr
-
Patent number: 6586476Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: October 28, 1999Date of Patent: July 1, 2003Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Publication number: 20020132795Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: ApplicationFiled: May 3, 2002Publication date: September 19, 2002Applicant: U.S. Bioscience, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 6204064Abstract: A method is disclosed for quantitatively measuring the progression of a lesion toward malignant disease by digitizing images of clinical samples of biopsied lesions using a microphotometer that includes a video camera, and a computer that includes a video frame capture board. The digitized image is analyzed to locate the borders of cell nuclei within the captured video image, and one or more chromatin texture features within such nuclei are processed by the computer to arrive at a numerical value. This numerical value is compared to a monotonic progression curve that has been previously established by using the same procedure on known clinical samples ranging from normal tissue to malignant disease. The method can also be used to test the efficacy of chemopreventive drugs and treatments.Type: GrantFiled: January 30, 1999Date of Patent: March 20, 2001Inventors: David S. Alberts, Peter H. Bartels
-
Patent number: 6060083Abstract: A method for treating palmar-plantar erythrodysethesia syndrome includes applying to affected areas a therapeutically effective amount of a dimethyl sulfoxide solution.Type: GrantFiled: April 1, 1999Date of Patent: May 9, 2000Assignee: Topical Technologies, Inc.Inventors: Robert T. Dorr, David S. Alberts
-
Patent number: 5994409Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: December 9, 1997Date of Patent: November 30, 1999Assignees: U.S. Bioscience, Inc., The Arizona Board of Regents on behalf of the University of ArizonaInventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 5985302Abstract: Methods, compositions and a kit for deactivating spills or leaks of HIV infected blood or anticancer drugs by applying to the leak or spill an aqueous solution containing calcium hypochlorite or sodium hypochlorite as the active ingredient. In order to thicken the aqueous solution and thus keep it from spreading beyond its intended area of application, the solution of calcium hypochlorite contains methylcellulose. In addition to chemically deactivating the active anticancer drug, the solution of the invention also effectively decolorizes it, thus preventing permanent stains on any surface or fabric with which the anticancer drug comes into contact.Type: GrantFiled: July 10, 1998Date of Patent: November 16, 1999Assignee: Supergen, Inc.Inventors: Robert T. Dorr, David S. Alberts
-
Patent number: 5851537Abstract: A salve includes a water-miscible, hydrophilic cream vehicle, 1-22% by weight a-DFMO, and no absorption enhancer. The salve is preferably contained in an ointment tube permanently sealed at one end to preclude exposure to light and air. The salve is applied as a preventative in an appropriate amount twice daily to skin exposed to actinic radiation. An initial application of a salve including 10% by weight A-DFMO is preferred to minimize the risk of skin irritation without compromising the therapeutic value of the salve. The salve shows no systemic uptake, thereby eliminating systemic toxicities that result from other techniques for administering the drug.Type: GrantFiled: January 31, 1997Date of Patent: December 22, 1998Assignee: Cancer Technologies, Inc.Inventors: David S. Alberts, Robert T. Dorr
-
Patent number: 5811113Abstract: Methods, compositions and a kit for deactivating spills or leaks of HIV infected blood or anticancer drugs by applying to the leak or spill an aqueous solution containing calcium hypochlorite or sodium hypochlorite as the active ingredient. In order to thicken the aqueous solution and thus keep it from spreading beyond its intended area of application, the solution of calcium hypochlorite contains methylcellulose. In addition to chemically deactivating the active anticancer drug, the solution of the invention also effectively decolorizes it, thus preventing permanent stains on any surface or fabric with which the anticancer drug comes into contact.Type: GrantFiled: November 6, 1992Date of Patent: September 22, 1998Assignee: Cancer Technologies, Inc.Inventors: Robert T. Dorr, David S. Alberts
-
Patent number: 5635506Abstract: This invention relates to a compound useful for the treatment of tumors having the formula: ##STR1##Type: GrantFiled: November 18, 1993Date of Patent: June 3, 1997Assignee: Research Corporation Technologies, Inc.Inventors: David S. Alberts, Robert T. Dorr, William A. Remers, Salah M. Sami
-
Patent number: 5246955Abstract: New cytotoxic quionones, designated amamitosenes and iminoazamitosenes are found to have significant activity against ovarian tumors, colon cancer, myecloma and the like neoplastic diseases.Pharmaceutical preparations and therapeutic regimens utilizing azamitosenes and iminoazamitosenes and their pharmaceutically active derivatives are disclosed.Type: GrantFiled: February 13, 1992Date of Patent: September 21, 1993Assignee: Research Corporation Technologies, Inc.Inventors: Edward B. Skibo, Imadul Islam, David S. Alberts